* M&A Update – Oct 24

∙$MYOV to be acquired by Sumitovant Biopharma for $27.00 cash per share, 50.3% premium, $2.9 billion
∙$CLR / Founder launched tender offer, expires Nov 21
∙$SRLP / Hartree Partners closing Nov 1
∙$RECP.to / $FFH.to shareholders approved deal, closing Oct 28
∙$BTRS / EQT filed PREM14a, no meeting date set, closing Q4/Q1
∙$AHPA deal vote
∙$BMAQ stockholders approved deadline extension to Jan 21, 9.7 million shares (84.6%) redeemed, 1.8 million remain, NAV $10.06
∙$CRU filed PRER14a to liquidate Nov 30, vote Nov 28, NAV $10.06
∙$OXAC filed DEF14a to extend deadline from Nov 16 to Aug 16 2023, vote Nov 9, NAV $10.21
∙$FOXW filed PRE14a to extend deadline to Apr 22 2023 (+3 months), vote Nov 30
∙$ESSC filed DEFM14a for NWTN deal, vote Nov 7
∙$BOAS stockholders approved Selina deal
∙$IGNY deal vote postponed to Oct 25
∙$AHPA deal vote
∙$EUCR extension vote
∙$BHSE redemption